PedAM
Pediatric Disease Annotations & Medicines
| Disease | adenocarcinoma |
| Symptom | C0004763|barrett\'s esophagus |
| Sentences | 46 |
| PubMedID- 22626608 | Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable. |
| PubMedID- 22241250 | Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus. |
| PubMedID- 23617676 | We report herein a case of adenocarcinoma arising from short-segment barrett's esophagus (ssbe) in a 36-year-old man. |
| PubMedID- 20397052 | Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23714382 | Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe). |
| PubMedID- 19660251 | Rapid progression of barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient. |
| PubMedID- 24737143 | Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23453294 | Patients: we studied 23 consecutive patients who underwent complete cesd for superficial esophageal carcinoma (22 squamous cell carcinomas and 1 adenocarcinoma associated with barrett's esophagus). |
| PubMedID- 24968432 | Pathological diagnosis was adenocarcinoma with barrett's esophagus. |
| PubMedID- 24681073 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus. |
| PubMedID- 21309910 | Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus. |
| PubMedID- 24212953 | Epidemiologic studies showed that long-term use of ppi was associated with lower rates of dysplasia and adenocarcinoma in patients with barrett's esophagus . |
| PubMedID- 21820152 | The findings of this study improve our understanding of the role that chromosomal instability and alterations of tumor suppressor genes such as cdkn2a and oncogenes such as erbb2 play in the progression of intestinal metaplasia to adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 26426603 | Cost-effectiveness decision tree model of endoscopic surveillance for esophageal adenocarcinoma among patients with definite barrett's esophagus. |
| PubMedID- 20698040 | The annual incidence of adenocarcinoma arising from barrett's esophagus (be) is approximately 0.5%. |
| PubMedID- 20610142 | In contrast to adenocarcinoma arising from barrett's esophagus in western countries, the major disease phenotype in the asia-pacific region is esophageal squamous cell carcinoma which is attributed to the prevalence of smoking, alcohol, and betel quid chewing. |
| PubMedID- 21991505 | Similarly, barrett's esophagus, a precursor of esophagus adenocarcinoma, is thought to have a low prevalence among asians. |
| PubMedID- 24651385 | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis. |
| PubMedID- 23606979 | barrett's esophagus is the source of barrett's adenocarcinoma and is characterized by the replacement of squamous epithelium with columnar epithelium in the lower esophagus due to chronic gastroesophageal reflux disease (gerd). |
| PubMedID- 22302717 | There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus. |
| PubMedID- 20188100 | Medications (nsaids, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 26233550 | Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 22272378 | found a correlation between cox2 expression and tp53 wild-type status in esophageal adenocarcinoma with barrett's esophagus as a precursor lesion, but not in scc, providing evidence that the participation of p53 in the regulation of cox2 expression in cancer may be dependent on tumor histology. |
| PubMedID- 25843080 | Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237). |
| PubMedID- 26208896 | Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 23605648 | Among the gi tract cancer, colorectal (crc) as well as esophageal cancer have raised the most attention over the past decades, as they both share a long precancerous stage (the adenoma in crc and barrett's esophagus in the case of esophageal adenocarcinoma) which provides a window of opportunity to intervene and prevent development of cancer.in this review, we will focus on both crc as well as esophageal adenocarcinoma (eac). |
| PubMedID- 23617672 | It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy. |
| PubMedID- 23111465 | While some studies suggest ppis result in a significant reduction in the risk of developing dysplasia and adenocarcinoma in patients with barrett's esophagus, others suggest that ppis have no effect. |
| PubMedID- 25071359 | Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23338150 | Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus. |
| PubMedID- 21995385 | Incidence of adenocarcinoma among patients with barrett's esophagus. |
| PubMedID- 21946284 | Whether nonerosive reflux disease (nerd) is a risk factor for barrett's esophagus (be), the precursor of esophageal adenocarcinoma, is unknown. |
| PubMedID- 23243384 | For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma. |
| PubMedID- 19850156 | Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: a systematic review and meta-analysis. |
| PubMedID- 19748616 | Background: barrett's esophagus is a precursor of esophageal adenocarcinoma, both of which are associated with gerd. |
| PubMedID- 21115135 | The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated. |
| PubMedID- 22796132 | Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept. |
| PubMedID- 21375764 | In contrast with the esophageal adenocarcinoma arising from barrett's esophagus in western countries, the major phenotype in the asia-pacific region is esophageal squamous cell carcinoma (escc) . |
| PubMedID- 24795040 | Background: proton pump inhibitors (ppis) may reduce the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus. |
| PubMedID- 26240798 | The incidence of esophageal adenocarcinoma arising from barrett's esophagus is about 0.5%. |
| PubMedID- 26202380 | Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk. |
| PubMedID- 26068095 | We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim. |
| PubMedID- 22443641 | Previously, the risk of progression to esophageal adenocarcinoma in patients with barrett's esophagus was thought to be approximately 1%. |
| PubMedID- 24605249 | Observational studies have shown that non-steroidal anti-inflammatory drugs could reduce the adenocarcinoma incidence in patients with barrett's esophagus by 41%, while statins could reduce the risk by 43%. |
| PubMedID- 23591735 | We suggest that it may be useful to stratify the risk of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 23525404 | For example, gej adenocarcinoma is associated with barrett's esophagus, while gastric cancer is associated with helicobacter pylori infection. |
Page: 1